“As a long-trapped shareholder of Sinovac, I demand a fair resolution supported by transparency. I strongly urge Sinovac’s Board of Directors to expedite the resumption of trading of Sinovac’s shares on NASDAQ. The Company is represented by the prestigious law firm of Latham & Watkins LLP and its audits are conducted by Grant Thornton LLP. Further, OrbiMed Advisors LLC, a multi-billion dollar investment group based in the USA, is a significant investor in Sinovac. I call upon all the parties I have listed herein to do their part to ensure that ALL shareholders receive a fair deal.

~ C.F., Los Angeles, California, USA

"I began investing in Sinovac in 2008 when I heard they were working on a vaccine for the H5N1 bird flu epidemic.  I felt the vaccine market in China could be big and it would be a good hedge against any future pandemics.  As a physician I was also impressed they authored articles that were published in major US medical journals. Needless to say, I have been extremely disappointed in the … company's leadership team, the endless lawsuits, the lack of transparency and the inability over the last 6 years in being able to access my money. How ironic that I was unable to have access to my shares when that pandemic did face the world! It is very disturbing to hear that $2.7 billion was distributed while our shares received nothing. I strongly support the call for transparency, and justice for long-standing shareholders who have been ignored for so many years.."

~ R.L & C.L., USA

As a shareholder of Sinovac, I believe we are entitled to the payout of the large profits that the company has been making since the share suspension. The money we have invested in the company has lost much of its value due to high inflation and the impossibility of trading. I really hope that the new leadership resolves this imbalance for the people who believed in the company at the time."

~ R.V., Belgium

"Thank you for taking action to get Sinovac trading again. I have been an investor in Sinovac for many years. As a stockholder I was extremely disappointed and even furious that we could not share in the company's fortunes during COVID. Here we are years later, and still no word from the board. The lack of transparency and the inaction of the board is unconscionable and unacceptable. We need a board that will act in the shareholders' best interests, who let us know immediately what are the board's plans to declare dividends, and when the stock will start trading."

~ J.B., Vail, Colorado, USA

"I knew Sinovac from 2003 with the first SARS epidemic. I bought shares right after they got listed on the Nasdaq. I have owned Sinovac shares for a long time. What I'm especially angry about is that after the Judgment of the Eastern Caribbean Court Of Appeal, they didn't take the opportunity to sit around a table and to (negotiate a settlement). That was in December 2021, the right moment to make an agreement. That was at the height of the Covid crisis and the shares of vaccine producers were skyrocketing. What a shame! Keep me informed about your actions please."

~ D.M., Belgium

"I have been a Sinovac shareholder for more than 10 years. I have followed the events and litigation that has happened at Sinovac for the past 6-7 years. Your Sinovac Chessboard showed that you put in a lot of effort to protect the interests of all shareholders of Sinovac. I hereby say thank you. Usually when a dividend is announced, the record and payment date is informed at the same time. In Sinovac's case, the new Board stated that they would work with management to determine such dates. That gives the impression that the new Board may not be in control of the management. Please correct me if I am wrong. I am particularly concerned to learn from the Chessboard that SAIF Partners on 18 March 2025 proposed a special shareholders' meeting to elect a new Board. Under the circumstances, the open letter to ask the Sinovac Board to distribute dividends, and the subsequent decision of the Sinovac Board, seems wise and prudent. I dread to think that the company continues to be involved in proxy fights and litigation and shareholders get nothing. That is not fair. Thank you and best regards."

~ G.A.L., Malaysia

"I am a long-term common shareholder of Sinovac. The initial $55 special cash dividend declared is too low and unfair. Please bear in mind that common shareholders, such as myself, lost out on a considerable windfall when trading of Sinovac shares was halted for six years. I humbly request that the Board of Directors increase the special dividend and inform shareholders when the shares will resume trading."

~ M.J., U.S.